NCT05738291View on ClinicalTrials.gov

A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

June 14, 2024

Study Completion Date

June 14, 2024

Conditions
Healthy
Interventions
DRUG

BI 1839100

BI 1839100

DRUG

Placebo matching BI 1839100

Placebo matching BI 1839100

DRUG

midazolam

midazolam

DRUG

digoxin

digoxin

DRUG

rosuvastatin

rosuvastatin

Trial Locations (1)

9728 NZ

ICON-Groningen-62040, Groningen

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05738291 - A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood | Biotech Hunter | Biotech Hunter